Received May 12, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | UNK | 93KK4 | — |
the second dose on February 2025; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of drug dose administration interval too long in a 75-year-old female patient who received Herpes zoster (Shingrix) (batch number 93KK4, expiry date 31-JAN-2027) for prophylaxis. Previously administered products included Shingrix (received 1st dose of Shingrix vaccine in 2018). In FEB-2025, the patient received Shingrix. In FEB-2025, an unknown time after receiving Shingrix, the patient experienced drug dose administration interval too long (Verbatim: the second dose on February 2025). The outcome of the drug dose administration interval too long was not applicable. Additional Information: GSK Receipt Date: 06-MAY-2025 The pharmacist called to verify if an extra Shingrix dose would be needed if patient received the first dose on 2018 and the second dose on February 2025, which led to drug dose administration interval too long. The Vaccine Administration Facility is the same as Primary Reporter.